70637-26-2

Basic information

• Product Name: (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate
• Synonyms: (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate;L-Phenylalanine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-, phenylmethyl ester;benzyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate
• CAS NO: 70637-26-2
• Molecular Formula: C₂₇H₃₆N₂O₅
• Molecular Weight: 468.58514
• Mol File: 70637-26-2.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate(70637-26-2)
• EPA Substance Registry System: (S)-benzyl 2-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate(70637-26-2)

Safety Data

• Hazardous Substances Data: 70637-26-2(Hazardous Substances Data)

Usage

Uses

Benzyl (tert-Butoxycarbonyl)-L-leucyl-L-phenylalaninate has a protein reactive electrophilic groups such as; epoxyketone and aziridinylketone.

Upstream product

• 3392-09-4 Boc-Leu-ONSu 
• 1738-78-9 L-phenylalanine benzyl ester p-toluene-sulfonic acid salt 
• 2462-32-0 L-phenylalanine benzyl ester hydrochloride 
• 15136-32-0 (N-(tert-butoxycarbonyl)-L-leucinyl)-L-phenylalanine methyl ester 
• 100-51-6 benzyl alcohol 
• 2688-22-4 Nps-L-Phe-OH 
• 84673-44-9 (S)-2-(2-Nitro-phenylsulfanylamino)-3-phenyl-propionic acid benzyl ester 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 962-39-0 L-Phenylalanine benzyl ester 
• 61-90-5 L-leucine 
• 63-91-2 L-phenylalanine 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 

Downstream Products

• 26055-05-0 N-[N-(tert-butoxycarbonyl)-L-leucyl]-L-phenylalanine 
• 15136-32-0 (N-(tert-butoxycarbonyl)-L-leucinyl)-L-phenylalanine methyl ester 
• 65671-74-1 Boc-L-Leu-D-Phe-OH 
• 70637-27-3 Leu-Phe-OBzl 
• 119256-89-2 (S)-2-[(S)-4-Methyl-2-(2,2,2-trifluoro-acetylamino)-pentanoylamino]-3-phenyl-propionic acid benzyl ester 
• 226922-59-4 (E)-(S)-4-[(S)-2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-phenyl-propionylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 859-45-0 N-trifluoroacetyl-leucylphenylalanine methylester 
• 59880-97-6 formyl-methionyl-leucyl-phenylalanine 
• 70637-30-8 H-Met-Leu-Phe-O-CH₂C₆H₅ 
• 70637-32-0 formyl-Met-Leu-Phe-OCH₂C₆H₅ 
• 70637-29-5 Boc-Met-Leu-Phe-OCH₂C₆H₅ 
• 70637-28-4 (S)-benzyl 2-((S)-2-amino-4-methylpentanamido)-3-phenylpropanoate TFA salt 
• 70691-56-4 L-leucyl-L-phenylalanine methyl ester hydrochloride 
• 1365292-39-2 L-isoseryl-L-leucyl-L-phenylalanine benzyl ester hydrochloride 

Relevant articles and documents

METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE COMPOUND, AND CATALYST AND FLOW PRODUCTION SYSTEM

PROBLEM TO BE SOLVED: To provide a new production method that allows a dehydration condensation reaction between carboxylic acid and amine, and a catalyst. SOLUTION: A method for producing a carboxylic acid amide compound includes the step for causing a r

Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy to Overcome Cancer Resistance to Carfilzomib and Bortezomib

Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined. The lack of a clear understanding of clinical PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies. Here, we designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1′ site. We show that a Cfz analog, 9, harboring a hydroxyl substituent at its P1′ position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz. These results suggest that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to bypass resistance mechanisms associated with Cfz and to provide additional clinical options for patients resistant to Cfz.

The greening of peptide synthesis

The synthesis of peptides by amide bond formation between suitably protected amino acids is a fundamental part of the drug discovery process. However, the required coupling and deprotection reactions are routinely carried out in dichloromethane and DMF, b